| Literature DB >> 23821131 |
M Czyż1, P Tabakow, A Weiser, B E Lechowicz-Głogowska, L W Zub, W Jarmundowicz.
Abstract
The aim of the study was to assess the safety and effectiveness of stereotactic brain tumour biopsy (STx biopsy) guided by low-field intraoperative magnetic resonance imaging (iMRI) in comparison with its frameless classic analogue based on a prospective randomized trial. A pilot group of 42 brain tumour patients was prospectively randomized into a low-field iMRI group and a control group that underwent a frameless STx biopsy. The primary endpoints of the analysis were postoperative complication rate and diagnostic yield, and the secondary endpoints were length of hospital stay and duration of operation. The iMRI group (21 patients) and the control group (21 patients) did not differ significantly according to demographic and epidemiological data. No major postoperative complications were noted in either group. In addition, no significant differences in the diagnostic yield (p = 1.00) and length of hospital stay (p = 0.16) were observed. The mean total OR time was 111 ± 24 min in iMRI and 78 ± 29 min in the control group (p = 0.0001). Usage of iMRI may prolong the time of the procedure but seems to be comparable in safety and effectiveness to the standard frameless STx biopsy.Entities:
Mesh:
Year: 2013 PMID: 23821131 PMCID: PMC3889652 DOI: 10.1007/s10143-013-0486-6
Source DB: PubMed Journal: Neurosurg Rev ISSN: 0344-5607 Impact factor: 3.042
Fig. 1Graphical illustration of the recruitment and randomization process. DGN diagnosed, STx biopsy stereotactic biopsy
Fig. 2A ferromagnetic passively navigated sidecut 2.2-mm biopsy needle. The solid triangle indicates a stopper, allowing to mark the depth of the needle insertion calculated by the neuronavigation system. Open triangles indicate passive neuronavigation markers. A close-up view of a 9-mm long cutting window of the biopsy needle allowing to obtain a tissue sample of the estimated volume of over 30 mm3 is visible in the lower-left corner
Fig. 3Example postoperative iMRI T1-weighted axial 4-mm control scans. a The left temporal lobe contrast-enhancing tumour. b The left frontal lobe non-enhancing pathology. The ferromagnetic biopsy needle has been removed prior to scanning. The biopsy site is visible as a black spot— a small air bubble is indicated by the open triangles
Fig. 4Schematic presentation of the intervention in both study and control group. STx biopsy stereotactic biopsy, post-op postoperative, e-steady iMRI scan modality routinely performed during preoperative positioning of the patient, ax axial scan orientation, min minutes, s seconds
Characteristics of the patients. Completed with the allocation information, demographic and epidemiological information as well as pathology description
| Allocation | Sex | Age | WHO | Maximum Diameter [mm] | Enhancement | Dominant hemisphere | Lobe | Pathology | |
|---|---|---|---|---|---|---|---|---|---|
| P 01 | Non-iMRI | Male | 36 | 3 | 26 | – | – | F + P | Limph |
| P 02 | iMRI | Female | 77 | 2 | 52 | + | – | T + P | Hgg |
| P 03 | Non-iMRI | Female | 67 | 2 | 45 | + | + | T + P | Hgg |
| P 04 | iMRI | Female | 60 | 2 | 55 | + | – | P | Hgg |
| P 05 | iMRI | Male | 46 | 2 | 69 | + | + | T | Hgg |
| P 06 | iMRI | Female | 64 | 1 | 25 | + | + | P | Infl |
| P 07 | Non-iMRI | Male | 57 | 1 | 60 | + | + | T + P | Limph |
| P 08 | Non-iMRI | Male | 56 | 2 | 29 | – | – | F | – |
| P 09 | Non-iMRI | Female | 40 | 2 | 31 | – | + | F | Lgg |
| P 10 | iMRI | Female | 77 | 3 | 69 | + | – | P | Hgg |
| P 11 | iMRI | Female | 48 | 2 | 64 | + | + | F | Hgg |
| P 12 | Non-iMRI | male | 47 | 2 | 64 | + | – | F | Hgg |
| P 13 | Non-iMRI | Female | 73 | 2 | 50 | + | + | P | Hgg |
| P 14 | Non-iMRI | Female | 65 | 3 | 77 | – | + | T + P | Lgg |
| P 15 | iMRI | Male | 73 | 3 | 39 | + | – | T | Limph |
| P 16 | iMRI | Male | 22 | 1 | 36 | – | + | F | Lgg |
| P 17 | Non-iMRI | Male | 61 | 2 | 45 | + | + | F | Hgg |
| P 18 | Non-iMRI | Male | 80 | 3 | 38 | – | – | T | Lgg |
| P 19 | iMRI | Male | 19 | 1 | 8 | + | – | T | Limph |
| P 20 | Non-iMRI | Male | 60 | 1 | 50 | + | + | F + T + P | Hgg |
| P 21 | Non-iMRI | Female | 77 | 3 | 42 | + | – | T | Hgg |
| P 22 | iMRI | Male | 44 | 1 | 60 | – | + | F + T | Lgg |
| P 23 | iMRI | Female | 46 | 3 | 24 | + | – | P | Limph |
| P 24 | iMRI | Male | 34 | 2 | 64 | + | + | T | Lgg |
| P 25 | iMRI | Male | 50 | 3 | 59 | + | – | P + O | Limph |
| P 26 | iMRI | Male | 64 | 2 | 60 | + | – | F | Hgg |
| P 27 | iMRI | Male | 63 | 2 | 35 | – | + | F + T | Lgg |
| P 28 | Non-iMRI | Male | 51 | 1 | 51 | + | + | T | Hgg |
| P 29 | Non-iMRI | Male | 38 | 0 | 90 | – | – | F + T + P | Lgg |
| P 30 | Non-iMRI | Male | 52 | 4 | 67 | + | – | F | Hgg |
| P 31 | iMRI | Male | 57 | 3 | 46 | + | – | F | Limph |
| P 32 | Non-iMRI | Male | 60 | 2 | 48 | + | – | T | Hgg |
| P 33 | Non-iMRI | Female | 71 | 2 | 52 | + | – | T | Hgg |
| P 34 | iMRI | Male | 50 | 1 | 74 | – | + | F + P | Lgg |
| P 35 | Non-iMRI | Male | 49 | 2 | 48 | + | + | P + O | Hgg |
| P 36 | Non-iMRI | Female | 32 | 0 | 71 | – | + | F | Lgg |
| P 37 | iMRI | Male | 32 | 1 | 16 | – | + | F | Infl |
| P 38 | iMRI | Female | 28 | 1 | 66 | + | + | T | Hgg |
| P 39 | Non-iMRI | Female | 63 | 2 | 80 | + | – | T + O | Hgg |
| P 40 | iMRI | Male | 72 | 3 | 62 | + | + | F | – |
| P 41 | Non-iMRI | Female | 29 | 0 | 75 | – | – | F + T | Lgg |
| P 42 | iMRI | Male | 60 | 2 | 35 | + | – | T | Lgg |
F frontal lobe, P parietal lobe, T temporal lobe, O occipital lobe, Lgg low grade gliomas, Hgg high grade gliomas, Limph liphoma, Infl inflammation
Independent variables analysed among iMRI and control group. Mean ± standard deviation, median with (interquartile range) or percentile values were expressed
| Variables | iMRI ( | Control ( |
|
|---|---|---|---|
| Age | 52 ± 17 | 55 ± 15 | 0.46 |
| Gender [male] | 67 % | 57 % | 0.75 |
| ECOG performance statusa | 2 (2) | 2 (1) | 0.86 |
| Maximum tumour diameter [mm] | 48 ± 19 | 54 ± 18 | 0.32 |
| Tumour enhancement ratio | 76 % | 62 % | 0.50 |
| Bleeding risk factorsb | |||
| Basal localization | 38 % | 43 % | 1.00 |
| Thalamic localization | 10 % | 19 % | 0.66 |
| Diabetes | 27 % | 27 % | 1.00 |
aEastern Cooperative Oncology Group performance status—a scale which provides information about neurological and social status and independency of patient with oncological disease
bAccording to McGirt et al. [17]
The summary of dependent variables supplemented by results of the statistical analysis. Mean ± standard deviation, median with (interquartile range) or percentile values were expressed
| Variables | iMRI ( | Control ( |
|
|---|---|---|---|
| Time [min] | |||
| Tprep | 53 ± 22 | 34 ± 20 | 0.004 |
| Top | 60 ± 26 | 44 ± 20 | 0.024 |
| TOR | 111 ± 24 | 78 ± 29 | <0.001 |
| Complications | |||
| Haematoma | 0 | 1 | 1.00 |
| Neurological deterioration | 0 | 0 | – |
| Infection | 0 | 0 | – |
| Diagnostic yield | 95 % | 95 % | 1.00 |
| Length of hospital stay [days] | |||
| LOSpre | 3 (4) | 4 (4) | 0.73 |
| LOSpost | 2 (4) | 2 (3) | 1.0 |
| LOSTOTAL | 5 (5) | 7 (3) | 0.16 |
Tprep—time of the preparation (period from the moment of conscious patient arriving to the operating room to the moment of skin incision), Top—time of the operation (period from the moment of skin incision to last suture insertion), TOR—total or time (Tprep + Top). LOSpre—preoperative length of hospital stay, LOSpost—postoperative length of hospital stay, LOSTOTAL—total length of hospital stay
Fig. 5Box graphs showing the differences between groups in a mean total length of hospital stay and b median total OR time. P values for Mann–Whitney U (a) and Student’s t test (b) are presented